Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.

The median age of chronic myeloid leukemia (CML) patients is ~60 years, and age is still considered an important prognostic factor, included in Sokal and EURO risk scores. However, few data are available about the long-term outcome of older patients treated with imatinib (IM) frontline. We analyzed the relationship between age and outcome in 559 early chronic-phase CML patients enrolled in 3 prospective clinical trials of Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party, treated frontline with IM, with a median follow-up of 60 months. There were 115 older patients (≥ 65 years; 21%). The complete cytogenetic and major molecular response rates were similar in the 2 age groups. In older patients, event-free survival (55% vs 67%), failure-free survival (78% vs 92%), progression-free survival (62% vs 78%), and overall survival (75% vs 89%) were significantly inferior (all P < .01) because of a higher proportion of deaths that occurred in complete hematologic response, therefore unrelated to CML progression (15% vs 3%, P < .0001). The outcome was similar once those deaths were censored. These data show that response to IM was not affected by age and that the mortality rate linked to CML is similar in both age groups. This trial was registered at www.clinicaltrials.gov as #NCT00514488 and #NCT00510926.

[1]  T. Mughal,et al.  Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase , 2010, Biologics : targets & therapy.

[2]  R. Latagliata,et al.  "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. , 2010, Leukemia research.

[3]  H. Terebelo,et al.  Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate. , 2010, Leukemia research.

[4]  Harold E. Nelson,et al.  Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. , 2010, The American journal of medicine.

[5]  S. Pal,et al.  Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment , 2010, CA: a cancer journal for clinicians.

[6]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Baccarani,et al.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. , 2009, Blood.

[8]  C. Carcassi,et al.  Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. , 2009, Blood.

[9]  Joerg Hasford,et al.  Epidemiology of chronic myeloid leukaemia (CML). , 2009, Best practice & research. Clinical haematology.

[10]  Giovanni Martinelli,et al.  Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. , 2009, Blood.

[11]  P. Galieni,et al.  Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. , 2009, Blood.

[12]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2009, Leukemia.

[13]  K. Rezvani,et al.  European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.

[14]  A. Schwarer,et al.  Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. , 2008 .

[15]  Martin C. Müller,et al.  Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV , 2008 .

[16]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[17]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. McMullin,et al.  Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients , 2008, Hematology.

[19]  M. Baccarani,et al.  Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome , 2008, Haematologica.

[20]  B. Druker,et al.  A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response , 2007, Clinical Cancer Research.

[21]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[22]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[23]  Susan O'Brien,et al.  Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. , 2006, Blood.

[24]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[25]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[26]  M. Gobbi,et al.  Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Russo Eleonora,et al.  Elderly patients with Ph+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment , 2005 .

[28]  M. Baccarani,et al.  Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. , 2004, Blood.

[29]  H. Kantarjian,et al.  Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome‐positive chronic myelogenous leukemia , 2003, Cancer.

[30]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[31]  S. Woolf,et al.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.

[32]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.

[33]  R. Greil,et al.  Interferon-a for the treatment of elderly patients with chronic myeloid leukaemia , 1998 .

[34]  J. Hasford,et al.  A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. , 1998, Journal of the National Cancer Institute.

[35]  M. Horowitz,et al.  Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. , 1996, Bone marrow transplantation.

[36]  H. Kantarjian,et al.  Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older , 1996 .

[37]  Sante Tura,et al.  Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.

[38]  Terry L. Smith,et al.  Old Age: A Sign of Poor Prognosis in Patients With Chronic Myelogenous Leukemia , 1987, Southern medical journal.

[39]  E. Gehan,et al.  Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. , 1985, Blood.

[40]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[41]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[42]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[43]  M. Gordon.  Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia , 2010 .

[44]  Martin C. Müller,et al.  Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) , 2010 .

[45]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[46]  H. Heimpel,et al.  Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany , 2009, Leukemia.

[47]  M. Baccarani,et al.  Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. , 2007, Haematologica.

[48]  H. Kantarjian,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[49]  M. Baccarani,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[50]  R. Brand,et al.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.

[51]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[52]  F. Mandelli,et al.  Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. , 2005, Leukemia research.

[53]  J. Garcia-conde,et al.  Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. , 2003, Haematologica.

[54]  H. Heimpel,et al.  Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. , 2003, Leukemia.

[55]  R. Greil,et al.  Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. , 1998, Leukemia research.

[56]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Lancet.

[57]  H. Kantarjian,et al.  Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. , 1996, The American journal of medicine.